Do analysts prefer QLGN or VRAX?

Virax Biolabs Group has a consensus price target of $25.00, indicating a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, QLGN or VRAX?

Virax Biolabs Group has higher revenue and earnings than Qualigen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A Virax Biolabs Group $10K 250.40 -$6.06M N/A N/A

Is QLGN or VRAX more profitable?

Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Virax Biolabs Group N/A N/A N/A

Do analysts prefer VRAX or JAGX?

Virax Biolabs Group presently has a consensus price target of $25.00, indicating a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Jaguar Animal Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, VRAX or JAGX?

Virax Biolabs Group has higher earnings, but lower revenue than Jaguar Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virax Biolabs Group $10K 250.40 -$6.06M N/A N/A Jaguar Animal Health $29.54M 0.06 -$53.43M -$591.92 N/A

Is VRAX or JAGX more profitable?

Virax Biolabs Group has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -169.04%. Company Net Margins Return on Equity Return on Assets Virax Biolabs Group N/A N/A N/A Jaguar Animal Health -169.04% N/A -115.55%

Do analysts rate BPTH or VRAX?

Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, BPTH or VRAX?

Virax Biolabs Group has higher revenue and earnings than Bio-Path. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Virax Biolabs Group $10K 250.40 -$6.06M N/A N/A

Is BPTH or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Virax Biolabs Group N/A N/A N/A

Do analysts rate ITRM or VRAX?

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Virax Biolabs Group 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, ITRM or VRAX?

Virax Biolabs Group has lower revenue, but higher earnings than Iterum Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Iterum Therapeutics $390K 4.10 -$24.77M -$0.75 N/A Virax Biolabs Group $10K 250.40 -$6.06M N/A N/A

Is ITRM or VRAX more profitable?

Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Virax Biolabs Group N/A N/A N/A

Which has stronger valuation and earnings, PPBT or VRAX?

Virax Biolabs Group has higher revenue and earnings than Purple Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$18.84 N/A Virax Biolabs Group $10K 250.40 -$6.06M N/A N/A

Is PPBT or VRAX more profitable?

Virax Biolabs Group's return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -123.63% -98.72% Virax Biolabs Group N/A N/A N/A

Virax Biolabs Group (VRAX) Competitors

$3.13 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.14 +0.01 (+0.26%)

As of 07/2/2026 07:59 PM Eastern

Compare

VRAX vs. QLGN, JAGX, BPTH, ITRM, and PPBT

Should you buy Virax Biolabs Group stock or one of its competitors? MarketBeat compares Virax Biolabs Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virax Biolabs Group include Qualigen Therapeutics (QLGN), Jaguar Animal Health (JAGX), Bio-Path (BPTH), Iterum Therapeutics (ITRM), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical products" industry.

How does Virax Biolabs Group compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:QLGN) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Virax Biolabs Group has higher revenue and earnings than Qualigen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Virax Biolabs Group	$10K	250.40	-$6.06M	N/A	N/A

3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Virax Biolabs Group had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Virax Biolabs Group	Neutral

Virax Biolabs Group has a consensus price target of $25.00, indicating a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Virax Biolabs Group	N/A	N/A	N/A

Summary

Virax Biolabs Group beats Qualigen Therapeutics on 10 of the 10 factors compared between the two stocks.

How does Virax Biolabs Group compare to Jaguar Animal Health?

Virax Biolabs Group (NASDAQ:VRAX) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Virax Biolabs Group has a net margin of 0.00% compared to Jaguar Animal Health's net margin of -169.04%.

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Jaguar Animal Health	-169.04%	N/A	-115.55%

Virax Biolabs Group presently has a consensus price target of $25.00, indicating a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts plainly believe Virax Biolabs Group is more favorable than Jaguar Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Virax Biolabs Group has higher earnings, but lower revenue than Jaguar Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$10K	250.40	-$6.06M	N/A	N/A
Jaguar Animal Health	$29.54M	0.06	-$53.43M	-$591.92	N/A

8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 2.0% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Virax Biolabs Group has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market.

In the previous week, Virax Biolabs Group had 1 more articles in the media than Jaguar Animal Health. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Jaguar Animal Health. Virax Biolabs Group's average media sentiment score of 0.00 equaled Jaguar Animal Health'saverage media sentiment score.

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Jaguar Animal Health	Neutral

Summary

Virax Biolabs Group beats Jaguar Animal Health on 10 of the 12 factors compared between the two stocks.

How does Virax Biolabs Group compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Bio-Path has a beta of -0.52, suggesting that its stock price is 152% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

In the previous week, Virax Biolabs Group had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Virax Biolabs Group	Neutral

Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher possible upside, analysts plainly believe Virax Biolabs Group is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Virax Biolabs Group has higher revenue and earnings than Bio-Path.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Virax Biolabs Group	$10K	250.40	-$6.06M	N/A	N/A

Virax Biolabs Group's return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Virax Biolabs Group	N/A	N/A	N/A

Summary

Virax Biolabs Group beats Bio-Path on 11 of the 11 factors compared between the two stocks.

How does Virax Biolabs Group compare to Iterum Therapeutics?

Iterum Therapeutics (NASDAQ:ITRM) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Virax Biolabs Group had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company	Overall Sentiment
Iterum Therapeutics	Neutral
Virax Biolabs Group	Neutral

Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

Virax Biolabs Group has lower revenue, but higher earnings than Iterum Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Virax Biolabs Group	$10K	250.40	-$6.06M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Virax Biolabs Group	N/A	N/A	N/A

Virax Biolabs Group has a consensus price target of $25.00, suggesting a potential upside of 698.72%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 45.1% of Virax Biolabs Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Virax Biolabs Group beats Iterum Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Virax Biolabs Group compare to Purple Biotech?

Purple Biotech (NASDAQ:PPBT) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

In the previous week, Virax Biolabs Group had 1 more articles in the media than Purple Biotech. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Purple Biotech. Purple Biotech's average media sentiment score of 0.00 equaled Virax Biolabs Group'saverage media sentiment score.

Company	Overall Sentiment
Purple Biotech	Neutral
Virax Biolabs Group	Neutral

Purple Biotech presently has a consensus target price of $30.00, suggesting a potential upside of 1,664.71%. Virax Biolabs Group has a consensus target price of $25.00, suggesting a potential upside of 698.72%. Given Purple Biotech's higher possible upside, equities research analysts plainly believe Purple Biotech is more favorable than Virax Biolabs Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Virax Biolabs Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virax Biolabs Group has higher revenue and earnings than Purple Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$18.84	N/A
Virax Biolabs Group	$10K	250.40	-$6.06M	N/A	N/A

Virax Biolabs Group's return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-123.63%	-98.72%
Virax Biolabs Group	N/A	N/A	N/A

Purple Biotech has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Virax Biolabs Group has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Virax Biolabs Group beats Purple Biotech on 7 of the 9 factors compared between the two stocks.

Get Virax Biolabs Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export

Metric	Virax Biolabs Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.49M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.61	28.02	24.70
Price / Sales	250.40	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.10	8.66	10.96	6.46
Net Income	-$6.06M	$23.81M	$3.57B	$337.01M
7 Day Performance	0.64%	3.39%	2.12%	1.69%
1 Month Performance	-41.08%	10.81%	5.25%	3.81%
1 Year Performance	-85.53%	62.61%	33.29%	23.90%

Virax Biolabs Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRAX Virax Biolabs Group	2.1243 of 5 stars	$3.13 flat	$25.00 +698.7%	-85.5%	$2.49M	$10K	N/A	5	News Coverage Analyst Downgrade Stock Split Gap Down
QLGN Qualigen Therapeutics	N/A	$1.18 +10.3%	N/A	-66.2%	$2M	N/A	N/A	50	Gap Up
JAGX Jaguar Animal Health	0.2972 of 5 stars	$3.04 +1.3%	N/A	-96.9%	$1.81M	$11.51M	N/A	50	Gap Up
BPTH Bio-Path	N/A	$0.04 -25.5%	N/A	-72.5%	$1.76M	N/A	N/A	10	Gap Down High Trading Volume
ITRM Iterum Therapeutics	0.0234 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRAX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virax Biolabs Group (VRAX) Competitors

VRAX vs. QLGN, JAGX, BPTH, ITRM, and PPBT

How does Virax Biolabs Group compare to Qualigen Therapeutics?

Summary

How does Virax Biolabs Group compare to Jaguar Animal Health?

Summary

How does Virax Biolabs Group compare to Bio-Path?

Summary

How does Virax Biolabs Group compare to Iterum Therapeutics?

Summary

How does Virax Biolabs Group compare to Purple Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virax Biolabs Group (VRAX) Competitors

VRAX vs. QLGN, JAGX, BPTH, ITRM, and PPBT

How does Virax Biolabs Group compare to Qualigen Therapeutics?

Which has more volatility and risk, QLGN or VRAX?

Which has higher earnings and valuation, QLGN or VRAX?

Do insiders & institutionals believe in QLGN or VRAX?

Does the media prefer QLGN or VRAX?

Do analysts prefer QLGN or VRAX?

Is QLGN or VRAX more profitable?

Summary

How does Virax Biolabs Group compare to Jaguar Animal Health?

Is VRAX or JAGX more profitable?

Do analysts prefer VRAX or JAGX?

Which has stronger earnings & valuation, VRAX or JAGX?

Do institutionals & insiders believe in VRAX or JAGX?

Which has more volatility & risk, VRAX or JAGX?

Does the media favor VRAX or JAGX?

Summary

How does Virax Biolabs Group compare to Bio-Path?

Which has more risk and volatility, BPTH or VRAX?

Does the media refer more to BPTH or VRAX?

Do analysts rate BPTH or VRAX?

Do institutionals and insiders hold more shares of BPTH or VRAX?

Which has stronger earnings and valuation, BPTH or VRAX?

Is BPTH or VRAX more profitable?

Summary

How does Virax Biolabs Group compare to Iterum Therapeutics?

Does the media prefer ITRM or VRAX?

Which has more volatility and risk, ITRM or VRAX?

Which has stronger valuation & earnings, ITRM or VRAX?

Is ITRM or VRAX more profitable?

Do analysts rate ITRM or VRAX?

Do institutionals and insiders hold more shares of ITRM or VRAX?

Summary

How does Virax Biolabs Group compare to Purple Biotech?

Does the media prefer PPBT or VRAX?

Do analysts prefer PPBT or VRAX?

Which has stronger valuation and earnings, PPBT or VRAX?

Is PPBT or VRAX more profitable?

Which has more volatility and risk, PPBT or VRAX?

Do insiders & institutionals hold more shares of PPBT or VRAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools